Home Shop Leupeptin (synthetic)

Leupeptin (synthetic)

ALX-260-009

Datasheet
Manual
SDS
CofA

Already have an account?

Cathepsin B inhibitor

GMP format available

Leupeptin is a competitive and reversible inhibitor of serine and cysteine proteinases like calpain, porcine kallikrein, trypsin, plasmin, papain and cathepsin B. Does not inhibit chymotrypsin and thrombin. Also known to inhibit activation-induced programmed cell death and restoration of defective immune responses of HIV⁺ donors.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

Product Details

Alternative Name	Acetyl-L-leucyl-L-leucyl-L-argininal . hemisulfate
Appearance	White to off-white powder.
CAS	103476-89-7
Formula	C₂₀H₃₈N₆O₄ . 0.5 H₂SO₄
MI	14: 5456
MW	426.6 . 49.0
Purity	≥97% (HPLC)
Solubility	Soluble in water, methanol or 100% ethanol.
Source	Synthetic.
Technical Info / Product Notes	Leupeptin gives multiple peaks on HPLC due to equilibria among three forms in solution. Purity determined using three main peaks. Majority of contaminating peptide is racemized leupeptin.

Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended.
Handling	Protect from light and moisture.
Long Term Storage	-20°C
Shipping	Ambient Temperature

Regulatory Status	RUO – Research Use Only

Late-onset Krabbe disease presenting as spastic paraplegia – implications of GCase and CTSB/D: Mächtel, R., Dobert, J. P., et al.; Ann. Clin. Transl. Neurol. 11, 1715 (2024), Abstract
Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models: Drobny, S., Boros, F. A., et al.; Transl. Neurodegener. 12, 31 (2023), Abstract
Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy: Braun, F., Abed, A., et al.; J. Clin. Invest. 133, (2023), Abstract
Autosomal dominant Zellweger Spectrum Disorder caused by de novo variants in PEX14 gene: H.R. Waterham, et al.; Genet. Med. , (2023), Abstract
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models: Prieto Huarcaya, S., Drobny, S., et al.; Autophagy 18, 1127 (2022), Abstract
GPR37 is processed in the N-terminal ectodomain by ADAM10 and furin: S.O. Mattila, et al.; FASEB J. 35, e21654 (2021), Abstract
F-Box Protein FBXW17-Mediated Proteasomal Degradation of Protein Methyltransferase PRMT6 Exaggerates CSE-Induced Lung Epithelial Inflammation and Apoptosis: Li, T., He, X., et al.; Front Cell Dev Biol 9, 599020 (2021), Abstract
Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified α-Synuclein Degradation Properties: Bunk, J., Prieto Huarcaya, S., et al.; Front Cell Dev Biol 9, 581805 (2021), Abstract
Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis: Marques, A. R. A., Di Spiezio, A., et al.; Autophagy 16, 811 (2020), Abstract
Inhibition of Cyclic Adenosine Monophosphate-Specific Phosphodiesterase by Various Food Plant-Derived Phytotherapeutic Agents: T. Röhrig, et al.; Medicines (Basel) 4, 80 (2017), Abstract — Full Text